Search results
Gilead expands FDA label for Biktarvy with Phase I pregnant HIV patient data
Clinical Trials Arena via Yahoo Finance· 21 hours agoThe expanded approval of Gilead’s Biktarvy was based on the Phase I trial data showing efficacy in...
Barclays cuts Gilead Sciences stock target, reiterates Equalweight rating By Investing.com
Investing.com· 18 hours agoOn Monday, Barclays made adjustments to its outlook on Gilead Sciences (NASDAQ:GILD), a...
Earnings call: Gilead reports robust Q1 growth, Trodelvy drives sales By Investing.com
Investing.com· 8 hours agoThe company's HIV product sales saw a 4% rise, while oncology product sales surged by 18%, primarily...
CDC says it's identified 1st documented cases of HIV transmitted through cosmetic needles
Medical Xpress· 23 hours agoThree women who were diagnosed with HIV after getting "vampire facial" procedures at an unlicensed...
Gilead has strong Q1, but updated 2024 EPS guidance range misses consensus
Seeking Alpha· 4 days agoGilead Sciences reports Q1 2024 financial results with a diluted EPS loss due to charges from...
FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV
Morningstar· 4 days agoGilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) approved...profile of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir ...
Gilead stock gains on revenue beat, despite a quarterly loss
Investing.com· 5 days agoGilead Sciences, Inc. (NASDAQ: GILD ) has reported a revenue increase in its first quarter of 2024,...
FDA Approves Label Update for Gilead’s Biktarvy to Include Pregnant Adults With HIV
Pharmaceutical Executive Magazine· 4 days agoGilead Sciences announced that the FDA has granted a label update to Biktarvy...
Gilead Sciences Posts Higher 1Q Sales, Swings to Loss on Charges
Market Watch· 4 days agoGilead Sciences posted higher first-quarter sales, but swung to a steep loss due to charges related to recent acquisitions, prompting the company to cut its per-share profit ...
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Zacks via Yahoo Finance· 18 hours agoGilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is...